Skip to main content
SpringerLink
Log in

No relevant influence on overall survival time in patients with metastatic breast cancer undergoing combination chemotherapy

  • Original Papers
  • Clinical Oncology or Epidemiology
  • Published:
Journal of Cancer Research and Clinical Oncology Aims and scope Submit manuscript

Summary

The results of clinical studies dealing with first and second line chemotherapy of metastatic breast cancer published between 1975 and early 1986 which involved 9350 women were reviewed. Our special aim was to evaluate combination chemotherapy and its influence on overall survival in late stage breast cancer patients. No significant improvement in overall survival times was found in this selected group of patients who were treated with intense palliative chemotherapy.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Berger MR, Bischof H, Fritschi E et al. (1985) Synthesis, toxicity, and therapeutic efficacy of 4-amino-N-(2′-aminophenyl)-benzamide: a new compound preferentially active in slowly growing tumors. Cancer Treat Rep 69:1415–1424

    Google Scholar 

  2. Berger MR, Floride J, Schmähl D et al. (1986) Estrogen-linked 2-chloroethylnitrosoureas: anticancer efficacy in MNU-induced rat mammary carcinoma, uterine activity in mice and receptor interactions. Eur J Cancer Clin Oncol 22:1179–1191

    Google Scholar 

  3. Muschiol C, Berger MR, Schuler B et al. (1987) Alkylphosphocholines: toxicity and anticancer properties. Lipids (in press)

  4. Patel JK, Nemoto T, Vezeridis M et al. (1986) Does more intense palliative treatment improve overall survival in metastatic breast cancer patients? Cancer 57:567–570

    Google Scholar 

  5. Petru E, Schmähl D (1986) On the relevance of “second-line” cytotoxic chemotherapy in patients with metastatic breast cancer resistant to standard combination. Wien Klin Wochenschr 98:790–797

    Google Scholar 

  6. Petru E, Schmähl D (1987) Bedeutung der Zusammensetzung verschiedener Kombinationsschemata bei der Chemotherapie des metastasierten Mammakarzinoms. Deutsch Med Wochenschr 112:270–275

    Google Scholar 

  7. Wingen F, Spring H, Schmähl D (1987) Antimetastatic effects of razoxane in a rat osteosarcoma model. Clin Expl Metastasis 5:9–16

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Institute of Toxicology and Chemotherapy, German Cancer Research Center, Im Neuenheimer Feld 280, D-6900, Heidelberg, Federal Republic of Germany

    E. Petru & D. Schmähl

Authors
  1. E. Petru
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. D. Schmähl
    View author publications

    You can also search for this author in PubMed Google Scholar

Additional information

Dedicated to Professor Dr. med. Dr. med. h.c. (mult) F. Linder, Heidelberg on the occasion of his 75th birthday

Rights and permissions

Reprints and permissions

About this article

Cite this article

Petru, E., Schmähl, D. No relevant influence on overall survival time in patients with metastatic breast cancer undergoing combination chemotherapy. J Cancer Res Clin Oncol 114, 183–185 (1988). https://doi.org/10.1007/BF00417834

Download citation

  • Received:

  • Accepted:

  • Issue Date:

  • DOI: https://doi.org/10.1007/BF00417834

Key words

Search

Navigation